Trial Profile

A Randomized, Double-blind, Placebo-controlled Parallel Group Phase 2a Study to Evaluate the Efficacy and Safety of HPG1860 in Subjects With Nonalcoholic Steatohepatitis

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Jun 2023 Results assessing safety, tolerability andefficacy of HPG1860 in patients with non-cirrhotic non-alcoholic steatohepatitis, presented at the European Association for the Study of the Liver Congress 2023.
25 May 2023 Results presented in the Hepagene Therapeutics Media Release.
25 May 2023 According to a Hepagene Therapeutics media release, data from this trial will be presented at the European Association for the Study of the Liver (EASL) Congress 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com